Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma

Leuk Lymphoma. 2015 Feb;56(2):368-76. doi: 10.3109/10428194.2014.919631. Epub 2014 May 27.

Abstract

The patient granulocyte-colony stimulating factor (G-CSF) response is represented by the leukocyte peak in the blood induced by a single dose of G-CSF after chemotherapy, and is correlated with subsequent neutropenic infection risk. General patterns for a meaningful risk group stratification, have not yet been determined. Two independent data sets including a total of 306 cases with myeloma or lymphoma and autologous blood stem cell transplant were available. An infection susceptibility curve plotted according to ranked G-CSF responses from a multicenter study reproduced and validated a curve from the previous single center. Two trend changes were seen within these curves at around 11,000 and 22,000 leukocytes/μL, which separated three groups with a high, medium and low risk of infection. While G-CSF response is related to the consecutive duration of neutropenia, it retains additional independent predictive information for infection risk (p<0.0001) and, more important, is a tool available before the onset of the critical period.

Keywords: G-CSF; autologous transplant; lymphoma; multiple myeloma; neutropenic infection.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bacterial Infections / etiology
  • Bacterial Infections / prevention & control
  • Combined Modality Therapy
  • Dose-Response Relationship, Drug
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Leukocyte Count
  • Linear Models
  • Lymphoma / therapy*
  • Male
  • Middle Aged
  • Multiple Myeloma / therapy*
  • Multivariate Analysis
  • Mycoses / etiology
  • Mycoses / prevention & control
  • Neutropenia / etiology
  • Neutropenia / prevention & control*
  • Risk Factors
  • Time Factors
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Granulocyte Colony-Stimulating Factor